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Novelty statement: 
x We have developed the first diabetes specific preference-based measures with United Kingdom 
value sets 
x The measures can be used to estimate Quality Adjusted Life Years for use the economic 
evaluation of diabetes specific interventions 
 
 
 
 
 
 
 
 
 
 
 Abstract: 
Aims:  
The aim of this study was to develop two diabetes specific preference-based measures (Diabetes 
Health Profile - 3 Dimension; DHP-3D and the Diabetes Health Profile ± 5 Dimension; DHP-5D) for use 
in the calculation of Quality Adjusted Life Years, a key outcome in economic evaluation. These 
measures were based on the non-preference-based instrument the Diabetes Health Profile. 
Methods:  
For DHP-3D, psychometric and Rasch analyses were used to develop a health state classification 
system based on the DHP-18. The DHP-5D added two dimensions to the DHP-3D to extend the range 
of impacts measured.  Each classification system was valued by 150 general public respondents in the 
United Kingdom using Time Trade Off.  Multivariate regression was to estimate utility value sets. The 
matched dimensions across each measure were compared using z score tests. 
Results:  
The DHP-3D included three dimensions defined as mood, eating and social limitations, and the DHP-5D 
added dimensions defined as hypoglycemic attacks and vitality.  For both, the random effects 
generalized least squares regression model produced consistent value sets, with the DHP-3D and DHP-
5D ranging from 0.983 (best state) to 0.717(worst state), and 0.979 to 0.618 respectively. The addition 
of the two extra dimensions leads to significant differences for the more severe levels of each matched 
dimension. 
Conclusions:  
We have developed two diabetes specific preference-based measures that, subject to psychometric 
assessment, can be used to provide condition specific utility values to complement generic utilities from 
more widely validated measures such as the EQ-5D.    
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Introduction 
For the economic evaluation of health interventions, the Quality Adjusted Life Year (QALY), which 
combines length and quality of life into a single figure, is a commonly used outcome.  The quality aspect 
(or utility value) is anchored on a 1 (full health) to 0 (dead) scale and can be derived from a preference-
based measure of health.  Preference-based measures include two elements, a health state 
classification system and a utility value set.  The utility value set is generally based on general 
population preferences for health states described by the measure and is elicited using a technique 
such as Time Trade Off[1] to produce values to input into QALYs. 
 
Generic preference-based measures s are widely used in the estimation of QALYs as they are 
developed for use across conditions.  The EuroQol-5 Dimension (EQ-5D) [2,3] is recommended by the 
UK National Institute for Health and Care Excellence [4], although it is also noted that the EQ-5D may 
not be relevant in all circumstances.  However, some generic measures may be insensitive in many 
patient groups because they do not cover important consequences of specific conditions [5,6]. In 
diabetes, there is some evidence for the psychometric validity of a range of generic measures, and 
some sensitivity to complications [7,8]. However, condition specific measures may provide more 
sensitive assessments of a condition. In diabetes one such measure is the Diabetes Health Profile 
(DHP-1/DHP-18) [9,10] which is used to provide a detailed assessment of emotional and behavioural 
health [11]. 
 
Condition specific measures cannot be used to directly estimate QALYs as they are not preference-
based. It is not possible to derive value sets for these measures given that they describe many millions 
of health states that would be too complex to value.  However, preference-based measures can be 
developed from existing measures to provide condition specific utilities [12]. This is done by developing 
a shortened health state classification system from the longer measure, and valuing the classification 
system using a preference elicitation technique with a general population sample.  The method has 
been applied widely in different conditions [13-18]. General population values are used in the 
development of preference-based measures, as in a publically funded healthcare system such as the 
UK, it is argued that it is the values of the tax payer funding the system that matters, and general 
population values that are recommended for use by the National Institute of Health and Care 
Excellence. 
 
The aim of this study was to develop two diabetes specific preference-based measures.  This includes 
the following objectives: 
1. To develop a health state classification system from the DHP-18 (DHP-3D). 
2. To extend the scope of the DHP-3D and develop a second classification system that captures 
additional dimensions of importance (DHP-5D). 
3. To generate utility value sets for both measures using Time Trade Off. 
 
The advantage of developing two preference-based measures is that utility values can be generated 
where only DHP-18 data is available (DHP-3D), and for other studies additional items can be included 
to estimate utilities reflecting a wider range of dimensions (DHP-5D). 
 
Methods: 
Measures ± DHP-18 
The DHP-18 [8] was developed from the longer DHP-1 and measures the psychosocial functioning 
across three domains: psychological distress, barriers to activity and disinhibited eating.The DHP-18 
has been used in clinical trials, health surveys and in the United Kingdom Department of Health long 
term condition measurement study [19-23]. 
 
Data 
The development of the DHP-3D was undertaken using data from a cross-sectional study of people with 
type 2 diabetes recruited at a hospital in South Yorkshire, UK (n=237; response rate 80.6%) categorized 
into three treatment groups: insulin (n=122); non-injectors/oral medication (n=37); Exenatide, an 
injectable medicine (n=78). The sample is older than the general population (65+: 44.1% vs.19.3%), and 
contains a larger proportion of men (61.8% vs. 48.7%) and retired people (55.5% vs.13.5%). 
 
Preference-based measure development process 
To develop the preference-based measures  we followed a five step process adapted from existing 
guidance [10]: 
 
Step 1 ± Dimensionality assessment 
DHP-3D 
Exploratory factor analysis detects structure in the relationship between items and was used to examine 
DHP-18 dimensionality. Factor loadings indicate the level of correlation between the item and the factor. 
The number of dimensions was indicated by the number of factors with eLJHQYDOXHV (meaning that 
the factor accounts for more variability than a single item) [24]. Items loading < 0.35 on any factor were 
excluded.  
 
DHP-5D 
To develop the DHP-5D, a diabetes clinician and research nurse were consulted about other relevant 
dimensions.  As part of this process, the authors and the clinicians discussed the dimensions included 
in the DHP-1, the generic EQ-5D and Short Form-36 (SF-36), and also other potentially important 
dimensions. 
 
Step 2 ± Item selection 
DHP-3D  
To develop the dimension descriptions we used classical psychometric and Rasch analysis [25] to firstly 
exclude and secondly select item(s) to represent the underlying dimension. Classical psychometrics 
included floor (proportion in worst category) and ceiling (proportion in the best category) effects and 
missing data.  Items with missing data <5% and floor/ceiling effects <80% were acceptable. 
 
Rasch analysis is an item response theory technique that converts categorical item responses into a 
continuous latent (logit) scale.  The probability of a response to each level of each item is used to 
assess the severity of the item against the underlying logit scale. To exclude items we assessed item 
response ordering, differential item functioning across age and gender subgroups and fit to the 
dimension model.  To select the best item the two key criteria were the spread of responses at the 
average item difficulty (at logit 0) and item severity range coverage.  
 
DHP-5D 
To develop the extra dimensions, relevant items were selected from an appropriate measure. 
 
Step 3 ± Validation 
The classification systems developed were validated by a diabetes clinician and research nurse who 
were shown the results of steps 1 and 2, and also the original measures, and asked their opinions on 
the item selected to represent each dimension in comparison to the others available. 
 
Step 4 ± Valuation study  
The valuation protocol used Time Trade Off with a sample of 300 UK general population respondents 
valuing nine health states each. 
 
State selection and sample allocation 
In the sections below, health states are described in terms of the levels of each dimension represented.  
For example DHP-3D state 111 represents a state including the best level, level 1, of each dimension.  
This will range to 444 which is the worst possible DHP-3D state.  For the DHP-5D, 33 unique states 
were selected using an orthogonal array, and allocated to four blocks of nine states (8 unique states 
plus the worst state).  For the DHP-3D, the same states excluding the two additional dimensions were 
valued.  This meant that 32 states were valued as state 111 was duplicated so appeared in two blocks.  
Each preference-based measure was valued by 150 respondents. 
 
Interview procedure and the composite Time Trade Off task 
Face-to-face interviews were carried out by a research agency.  Firstly, respondents completed 
demographic questions, and the classification system to be valued.  They were informed that the states 
relate to diabetes and ranked those included in the block in order of preference.   
 
The Time Trade Off task used the µVWDQGDUG¶method for states better than dead [2] and Lead Time- 
Time Trade Off [26] for states worse than dead.  For states better than dead, respondents chose 
between 10 years in a health state (life A) and between 0 and 10 (x) years in full health (life B).  The 
amount of time in full health was varied following a set iterative process until indifference was reached, 
with the value calculated as x/10. For states worse than dead (where 0 years in life B was preferable to 
10 years in life A), a µlead time¶RI\HDUVLQ full health was added to each option. Respondents then 
chose between 10 years in full health followed by 10 years in the health state(life A), or between 0 and 
20 (x) years in full health (life B). 
 
Recruitment 
Recruitment was carried out across the United Kingdom.  Firstly, respondents were recruited via an 
existing database of people interested in completing research studies. Respondents were provided with 
the study information and asked to participate.  Secondly, interviewers approached new respondents in 
a neutral location such as a coffee shop or library, provided them with the study information and asked 
them to take part.  7KHLQWHUYLHZVWRRNSODFHHLWKHULQWKHUHVSRQGHQWV¶KRPHRULQa public place and 
participants received a £25 incentive.  This process was approved by the School of Health and Related 
Research Ethics Committee at The University of Sheffield.  
 
Exclusion criteria and data analysis 
Respondents who valued every health state the same (but not at 1) were excluded.  This is because it is 
expected that respondents should value states differently if they are willing to trade some time, but 
valuing every state at one indicates not giving up any time which could be a genuine preference. 
Respondents who valued the worst state (444 or 44445) the highest were also excluded as this 
indicates lack of understanding.   
 
Step 5 ± Modelling  
Individual and mean-level multivariate regression was used to estimate utility values for all states. The 
models estimated preference weights for each dimension severity level (with no problems the baseline). 
TKHFODVVLILFDWLRQV\VWHPVDUHYDOXHGDJDLQVWµFull health¶which is given a value of 1 with instrument-
specific full health equivalent to the constant term. 
 
Health state utilities were estimated using the following function: 
itiij xgU HE  )( '          (1) 
Where ijU  gives the Time Trade Off disvalue which is calculated as 1 minus the  Time Trade Off  
value, i(1, 2..n) is the number of health states, j(1,2,.,.m) is the number of respondents, g specifies the 
functional form and itH  is the error term. Xi is a vector of binary dummy variables for each level of each 
dimension where the best level represents the baseline.  The models included ordinary least squares 
regression, random effects generalized least squares to account for repeated observations, and RE 
Tobit to account for the bounded nature of the data (where -Uij Ordinary Least Square  models 
comprising one mean value per health state were also estimated. 
 
Model performance criteria included the number of inconsistencies and significant coefficients within 
each dimension, root mean squared error and mean absolute error at the state level, and the number of 
states with absolute error greater than 5% and 10%.  Plots of actual and predicted values were 
examined. 
 
To compare the matched dimensions across the DHP-3D and DHP-5D we compared the difference 
across each level coefficient using the standardized z-score test 
z = (ȕ1 - ȕ¥VHȕ12 + seȕ22)    (2) 
where ȕ1 and ȕ2 are the coefficients for each level of each dimension.  A z-score of 1.96 or more 
indicates a significant difference at the 5% level. 
 
Results  
Step 1 ± Dimensionality 
DHP-3D 
A three dimension model was suggested (Table 1).  Dimension 1 (Mood) includes six items from the 
psychological distress factor (explaining 34.9% of the variance). Dimension 2 (Eating) includes five 
items from the disinhibited eating factor plus one barriers to activity item (explaining12.6%).  Dimension 
3 (social limitations) includes five barriers to activity items (explaining 9.6%).  One barriers to activity 
item (Frightening going into busy shops) cross loaded so was excluded. 
 
HCS2 
Expert input based on the DHP-1 and SF-36 suggested the use of two extra dimensions that are key 
features of diabetes: µ+\SRJO\FHPLF$WWDFNV¶DQGµ9LWDOLW\¶.  
 
Step 2 ± Dimension development ± DHP-3D 
The psychometric and Rasch analyses are shown in Table 1. Missing data rates are low (0-2.5%), and 
ceiling (17.3%-62.0%) and floor effects (3.8%-22.8%) were acceptable, and therefore do not clearly help 
to differentiate items. 
 
Psychological distress 
Items 6 and 16 were disordered between the middle response categories (sometimes/usually and 
sometimes/often respectively). Item 15 displayed differential item functioning by gender. The remaining 
items (8,17,18) had goodness of fit within the required parameters. Item 18 ³'R\RXILQG\RXUVHOIORVLQJ
\RXUWHPSHURYHUVPDOOWKLQJV"´covered the more severe end of the scale and was selected. 
 
Eating 
Items 7 and 12 displayed disordering between the middle response categories (sometimes/usually and 
a little/a lot respectively) and item 10 displayed differential item functioning by gender.  The three 
remaining items (1,5,9) displayed goodness of fit. Item 9 ³:KHQ\RXVWDUWHDWLQJKRZHDV\GR\RXILQGLW
WRVWRS"´had the largest spread at logit 0 and the largest severity range so was selected. 
 
Social limitations 
The middle response categories of Items 2 and 4 (sometimes/usually) and items 11 and 14 (a little/a lot) 
were disordered. Item 3 ³'RHVKDYLQJGLDEHWHVPHDQ\RXUGD\VDUHWLHGWRPHDOWLPHV"´remained for 
selection and covered a large severity range so was selected. 
 
Step 2 ± Dimension development ± DHP-5D 
For the DHP-5D the same items as the DHP-3D were used for the matched dimensions along with the 
items for the extra two dimensions described below. 
 
Hypoglycemic attack 
The DHP-1 includes four items UHSUHVHQWLQJWKLVGLPHQVLRQ³KDYLQJQDJJLQJIHDURIK\SRV´³DYRLGLQJ
JRLQJWRRIDULQFDVHRIK\SRV´³ZRUU\DERXWGRLQJWRRPXFKDQGJRLQJK\SR´DQG³ZRUU\DERXWJRLQJ
LQWRDGLDEHWLFFRPD´7KHLWHPUHODWLQJWR³worry about doing too much and going K\SR´was selected 
as it describes the dimension in more general terms. 
 
Vitality 
The SF-36 vitality dimension includes four items measuring energy, tiredness, being worn out and being 
full of life.  The positively worded items were excluded as these may cause issues with the overall 
perception of the health states by respondents.  Of the two negatively worded items, the more general 
item asking about frequency of feeling tired was selected.  
 
Step 3 ± Validation 
The diabetes clinician and research nurse validated the items selected for both the DHP-3D and DHP-
5D.  The items selected were therefore rewritten to generate the health state classification systems for 
valuation (Figure 1). 
 
Step 4 ± Valuation study  
Sample 
Overall, 300 interviews were fully completed (150 DHP-3D; 150 DHP-5D) with no significant 
demographic differences between the respondent samples (Table 2).  The sample differed to the UK 
population, with a higher proportion of women, younger people and students, and less retired people.  A 
substantial proportion of the sample had experience of diabetes in themselves, their family or in caring 
for others. 
 
Descriptive statistics and exclusions 
Eight respondents were excluded from the DHP-3D (six valued all states the same, and two valued the 
worst state highest) and three (who valued all states the same) from the DHP-5D.  DHP-3D mean 
values ranged between 0.965 (111) and 0.708 (444) and DHP-5D mean values were from 0.979 
(11111) to 0.618 (44445). The mean value generally decreases as the severity of the state (indicated by 
the sum score) increases. The online supplement includes all descriptive statistics for all of the 
observed Time Trade Off values for each instrument. Figure 2 displays the value distributions, with very 
few states valued negatively (or worse than dead). 
 
Step 5 ± Modelling  
DHP-3D  
Model 2 (Random Effects Generalised Least Squares) was preferred as it includes a higher number of 
significant parameters and has good predictive ability, with the lowest root mean squared error and 
percentage of absolute errors (Table 3). The constant is equivalent to instrument specific full health, so 
to calculate the utility value the decrement for each level is subtracted from this value.  For example, 
state 333 would be calculated as (0.983 ± 0.100 (L3 mood) ± 0.069 (L3 eating) ± 0.051 (L3 social) = 
0.763). The predicted values vary from 0.983 (111) to 0.717(444). Mood has the largest overall 
decrement followed by eating and social limitations. There is no systematic difference in the observed 
and predicted mean values by state severity (Figure 3).  
 
DHP-5D 
The Random Effects Generalised Least Squares model (model 7) found that the eating and social 
limitations dimensions were disordered between levels 3/4 and 2/3 respectively (Table 3).  These levels 
were combined to produce the ordered RE GLS model (model 8). The predicted values varied from 
0.979 for state 11111 to 0.618 for the state 44445. Vitality had the largest decrement followed by 
hypoglycaemic attacks. Again there was no systematic difference in the observed and predicted values 
(Figure 3).  
 
The z-score comparison of the Random Effects Generalised Least Squares models (model 2 for DHP-
3D and model 8 for the DHP-5D) demonstrates that the addition of the two extra dimensions leads to 
significant differences for levels 3 and 4 of each matched dimension. For the majority of the levels 
(except eating levels 2 and 3), the addition of the extra DHP-5D dimensions reduces the magnitude of 
the coefficients.  
 
Discussion 
The measurement of condition specific utilities can provide additional information for use in estimating 
QALYs. In this study we have developed two diabetes specific PBMs. The DHP-3D can be used to 
estimate QALYs for the assessment of diabetes specific interventions where the DHP-18 or DHP-1 is 
used.  The DHP-5D can be used to estimate QALYs when the DHP-1 plus the extra SF-36 item are 
included.   
 
The instruments developed in this study are not the first diabetes specific preference-based measures, 
with the Diabetes Utility Index (DUI) [27,28] derived from the Audit of Diabetes Dependent Quality of 
Life (ADDQoL).  The DUI includes five dimensions (Physical Ability/Energy, Relationships, 
Mood/Feelings, Enjoyment of Diet, and Satisfaction with Management of Diabetes). There is limited 
overlap in the dimensionality of the DUI and DHP-3D/DHP-5D (which is linked to the scop
measures) and the valuation method (which was Standard Gamble with patients in the United States). 
This study used Time Trade Off with the UK general population for comparability with the valuation of 
EQ-5D, and therefore we have produced the first of diabetes specific preference-based measures with 
UK value sets.  
 
The DHP-3D and DHP-5D cover a small utility scale range in comparison to the EQ-5D [1].  This 
reflects the mildness of the descriptive system which measures the day-to-day impact of diabetes that 
may not be perceived as severe in comparison to losing years of life in the Time Trade Off exercise.  
The more severe impact of the longer term complications of diabetes is not explicitly measured.    
 
Developing two classifications mean that utility values can be generated where only DHP-18 data is 
available, and for studies collecting new data additional items can be used to generate utility values that 
are able to reflect a wider range of dimensions.  The number of health states described by each 
measure is substantially different (64 vs. 1280).  This impacts on the overall utility range and has 
implications for the sensitivity of the measures to change over time, with the DHP-5D potentially having 
increased sensitivity.  However the change in utility value between DHP-5D health states may be 
smaller than the DHP-3D given that 1280 states cover a utility range of 0.361 in comparison to 64 states 
covering a range of 0.220. It is also worth noting the potential loss of information in reducing the longer 
DHP-18 to a shorter classification system.  In generating the short form, it is the aim of the analysis to 
retain as much information as possible to represent the dimensions included in the longer measure. 
Therefore factor, psychometric and Rasch analysis was used to understand the most representative 
dimension structure, and select the most valid item(s) to represent each domain. 
 
The additional dimensions of the DHP-5D also change the magnitude of the coefficients of the  
DHP-3D dimensions, with significant differences found for the more severe levels of each.   
This demonstrates the importance of vitality and hypoglycemic attacks, and the impact that these 
dimensions have on the overall importance of the matched dimensions.  The difference is mainly driven 
by the inclusion of vitality, a more generic dimension which has the largest decrement.  
 
Across the two measures there is also a difference in the percentage of the total states included in the 
valuation study, with (50% of DHP-3D states and 2.5% of DHP-5D).  This was done given the 
widespread use of the DHP-18 in existing studies [19-23] and the practicalities of using the DHP-5D 
which may require the inclusion of other measures, or the addition of extra items. However, both models 
produce ordered utility scales, so this may not be a concern. 
 
This study has limitations. Firstly, the development dataset did not include sufficient sample to allow for 
validation of the classification systems as has been done for other condition specific preference-based 
measures [14,16].  However, we did use expert input for validation as recently done by Mukuria et al 
[13], and this provides a strong basis for the dimensions and items included. Secondly, the sample who 
valued the measures is also not directly representative of the UK general population with more young 
people taking part, and it may be possible that older people would value diabetes specific health states 
differently.  However, a many of the sample had experience of diabetes and this could help inform 
preferences. Thirdly, it is possible that other dimensions that are important in diabetes were not included 
in the DHP-5D, for example weight gain.  However no data on useful pre-existing items to represent this 
dimension were found so weight gain was not included.  
 
The aim of preference-based measures is to apply general population values to the self-reported health 
of people with diabetes to facilitate decision making.  It is unclear whether diabetes patients have the 
same values for the health states as the general population, and this is an area for further work.  
 
We have yet to establish the psychometric validity of the DHP-3D and DHP-5D in comparison to generic 
measures such as the EQ-5D.  This is important as generic measures are widely used and accepted by 
reimbursement agencies such as the National Institute for Health and Care Excellence.  Therefore the  
validation of condition specific preference-based measures in comparison to generic instruments is a 
key area for further work as this evidence  will support the use of the DHP-3D and DHP-5D in the 
estimation of QALYs.  It is worth noting that the DHP-18 and EQ-5D have a level of validity for use in 
the assessment of diabetes related health status [8,29,30].  
 
In conclusion, we have developed two diabetes specific preference-based measures that, subject to 
psychometric assessment, we suggest for use to provide condition specific utility values to complement 
generic utilities from more widely validated measures.    
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Table 1: Dimension structure, psychometric and Rasch analysis of the DHP-18 
Dimension DHP-18 
dimension1 
Loading Psychometric analysis Rasch analysis 
 
  % at 
ceiling 
% at 
floor 
% missing 
data 
Disordered Differe
ntial 
Item 
Functi
oning 
Fit 
resid
ual 
Chi p 
value 
Spread at 
logit 0 
Item range 
Psychological distress 
           
Q6: Lose temper if people keep on at you PD 0.68 53.2 8.0 2.1 Yes 
(Sometimes/usually) 
     
Q8: More arguments due to diabetes PD 0.78 62.0 4.2 1.3   -0.42 0.22 0.37 to 0.84 -1.65 to 0.53 
Q15: Get depressed PD 0.59 38.0 7.6 0  Gender     
Q16: Lose temper or shout PD 0.99 46.4 6.3 0 Yes 
(Sometimes/often) 
     
Q17: Get touchy or moody PD 0.72 46.8 4.6 0   -0.45 0.72 0.14 to 0.85 -1.72 to 1.85 
Q18: Lose temper over small things PD 0.83 32.5 7.2 0   -0.20 0.68 0.04 to 0.70 -0.87 to 3.16 
Eating 
           
Q1: Food control life BA 0.60 24.9 7.2 2.1   0.66 0.41 0.20 to 0.85 -1.71 to 1.37 
Q5: Eat to cheer self up DE 0.68 31.6 6.3 1.7   -0.68 0.31 0.30 to 0.85 -1.71 to 0.85 
Q7: Hard saying no to foods DE 0.73 17.6 14.2 1.7 Yes 
(sometimes/usually) 
     
Q9: Easy to stop eating DE 0.64 17.3 3.8 0.4   0.03 0.91 0.11 to 0.93 -2.64 to 2.04 
Q10: Eat more when bored/fed up DE 0.67 10.5 16.9 0.4  Gender     
Q12: Wish not so many nice things to eat DE 0.49 29.1 22.8 0 Yes (a little/a lot)      
Social limitations 
           
Q2: Difficult staying out late BA 0.63 52.3 5.5 2.1 Yes 
(usually/sometimes) 
     
Q3: Days tied to meal times BA 0.73 34.6 3.8 2.5   -0.76 0.11 0.11 to 0.88 -2.01 to 2.10 
Q4: Avoid going out if sugars low BA 0.71 49.8 11.8 2.5 Yes 
(usually/sometimes) 
     
Q11: Worry about getting colds/flu BA 0.39 48.9 7.2 0.4 Yes (a little/a lot)      
Q14: Get edgy BA 0.53 55.3 6.8 2.1 Yes (a little/a lot)      
Excluded for non-loading  
           
Q13: Frightening going into busy shops BA           
1 PD: Psychological Distress; BA: Barriers to Activity; DE: Disinhibited Eating. Item in italics chosen for descriptive system
Table 2: Valuation study demographics 
 
Demographic DHP-3D  
n (%) 
DHP-5D  
n (%) 
Significance United Kingdom 
% 
Completion 150 150   
Male 61 (40.7) 65 (43.3) 0.64 48.7 
Age      
Mean (SD) 34.7 (14.2) 37.0 (14.8) 0.18 N/A 
Range 18-82 18-74  N/A 
Distribution   0.76  
18-40 100 (66.7) 94 (62.7)  41.6 
41-65 45 (30.0) 51 (34.0)  39.1 
Over 65 5 (3.3) 5 (3.3)  19.3 
Ethnicity   0.37  
White British 116 (77.3) 125 (83.3)  85.7 
White (other) 19 (12.7) 9 (6.0)  6.5 
Mixed race 3 (2.0) 4 (2.7)  1.2 
Asian 6 (4.0) 5 (3.3)  4.4 
Black 4 (2.7) 3 (2.0)  2.0 
Marital status   0.20  
Married/partner 75 (50.0) 86 (57.3)  N/A 
Single 64 (42.7) 59 (39.3)  N/A 
Separated/divorced/widowed 11 (7.3) 5 (3.3)  N/A 
Employment   0.45  
Employed 94 (62.7) 100 (66.7)  60.9 
Retired 7 (4.7) 10 (6.6)  13.5 
Student  44 (29.3) 33 (22.2)  7.3 
Other 5 (3.3) 7 (4.7)  18.3 
Education post minimum 140 (93.3) 136 (90.7)  0.40 N/A 
Has degree level education 92 (61.3) 97 (64.7) 0.55 N/A 
Householder status   0.25  
Own home 92 (61.3) 93 (62.0)  68.7 
Rent 53 (35.3) 56 (37.3)  31.3 
Experience of serious illness     
Yourself 27 (18.0) 30 (20.0) 0.91 N/A 
Family 113 (75.3) 110 (73.3) 0.54 N/A 
Caring for others 52 (34.7) 48 (32.0) 0.78 N/A 
Diabetes     
Yourself 2 (1.3) 8 (5.3) 0.05 N/A 
In family 68 (45.3) 57 (38.0) 0.43 N/A 
In caring for others 26 (17.3) 26 (17.3) 1.00 N/A 
Has long term health condition 48 (32.0) 55 (36.7) 0.40 N/A 
Time off work/other ill last 4 weeks 16 (10.7) 28 (18.7) 0.05 N/A 
 Table 3: Regression models estimating preference weights for the DHP-3D and DHP-5D 
 DHP-3D (Coef. (SE)) DHP-5D Z-score 
 (1) OLS (2) RE-
GLS 
(3) RE-
Tobit 
(4) RE-
Tobit 
(marginal 
effects) 
(5) Mean 
Model 
(6) OLS (7) RE-
GLS 
(8) RE-GLS 
Consistent 
model 
(9) RE-
Tobit 
(10) RE-Tobit 
Marginal 
effects 
(11) 
Mean 
Model 
2 vs 8 
Mood level 2 -0.030*** 
(0.008) 
-0.026*** 
(0.009) 
-0.038*** 
(0.010) 
-0.025*** 
(0.007) 
-0.029* 
(0.015) 
-0.021** 
(0.008) 
-0.016 
(0.010) 
-0.015 
(0.010) 
-0.019* 
(0.010) 
-0.016* 
(0.009) 
-0.021 
(0.012) 
-1.22 
Mood level 3 -0.098*** 
(0.016) 
-0.085*** 
(0.010) 
-0.100*** 
(0.011) 
-0.072*** 
(0.009) 
-0.098*** 
(0.015) 
-0.026** 
(0.013) 
-0.027** 
(0.011) 
-0.027** 
(0.011) 
-0.032*** 
(0.012) 
-0.027*** 
(0.010) 
-0.026* 
(0.012) 
-3.90** 
Mood level 4 -0.143*** 
(0.018) 
-0.127*** 
(0.010) 
-0.144*** 
(0.011) 
-0.110*** 
(0.009) 
-0.139*** 
(0.015) 
-0.060*** 
(0.016) 
-0.051*** 
(0.012) 
-0.051*** 
(0.011) 
-0.054*** 
(0.012) 
-0.047*** 
(0.010) 
-0.060*** 
(0.012) 
-5.11** 
Eating level 2 -0.004 
(0.012) 
0.000 
(0.010) 
-0.001 
(0.011) 
-0.001 
(0.008) 
-0.004 
(0.015) 
-0.042*** 
(0.012) 
-0.026** 
(0.012) 
-0.026** 
(0.012) 
-0.029** 
(0.012) 
-0.024** 
(0.010) 
-0.042*** 
(0.012) 
1.66 
Eating level 3 -0.066*** 
(0.012) 
-0.060*** 
(0.010) 
-0.069*** 
(0.010) 
-0.053*** 
(0.008) 
-0.065*** 
(0.015) 
-0.059*** 
(0.012) 
-0.045*** 
(0.011) 
-0.043*** 
(0.010) 
-0.050*** 
(0.011) 
-0.043*** 
(0.010) 
-0.059*** 
(0.012) 
2.62** 
Eating level 4 -0.058*** 
(0.010) 
-0.074*** 
(0.010) 
-0.083*** 
(0.010) 
-0.065*** 
(0.008) 
-0.053*** 
(0.015) 
-0.043*** 
(0.010) 
-0.041*** 
(0.011) 
-0.043*** 
(0.010) 
-0.045*** 
(0.011) 
-0.039*** 
(0.009) 
-0.043*** 
(0.012) 
-2.19** 
Social limitations level 2 0.011 
(0.012) 
-0.022** 
(0.010) 
-0.026** 
(0.011) 
-0.019** 
(0.008) 
0.011 
(0.015) 
-0.005 
(0.011) 
-0.014 
(0.011) 
-0.012 
(0.010) 
-0.018 
(0.011) 
-0.015 
(0.010) 
-0.005 
(0.012) 
-0.07 
Social limitations level 3 -0.003 
(0.020) 
-0.044*** 
(0.012) 
-0.051*** 
(0.013) 
-0.039*** 
(0.010) 
-0.003 
(0.015) 
-0.001 
(0.016) 
-0.009 
(0.013) 
-0.012 
(0.010) 
-0.014 
(0.013) 
-0.012 
(0.011) 
-0.001 
(0.012) 
-2.05** 
Social limitations level 4 -0.044*** 
(0.010) 
-0.065*** 
(0.009) 
-0.071*** 
(0.010) 
-0.055*** 
(0.008) 
-0.039** 
(0.015) 
-0.026** 
(0.010) 
-0.029*** 
(0.010) 
-0.029*** 
(0.010) 
-0.034*** 
(0.010) 
-0.029*** 
(0.009) 
-0.026** 
(0.012) 
-2.68** 
Hypoglycaemic attacks 
level 2 
     -0.025** 
(0.011) 
-0.019* 
(0.010) 
-0.019* 
(0.010) 
-0.022** 
(0.010) 
-0.018** 
(0.008) 
-0.025* 
(0.012) 
 
Hypoglycaemic attacks 
level 3 
     -0.036*** 
(0.013) 
-0.035*** 
(0.011) 
-0.036*** 
(0.011) 
-0.041*** 
(0.012) 
-0.035*** 
(0.010) 
-0.036*** 
(0.012) 
 
Hypoglycaemic attacks 
level 4 
     -0.067*** 
(0.009) 
-0.065*** 
(0.010) 
-0.065*** 
(0.010) 
-0.070*** 
(0.010) 
-0.061*** 
(0.008) 
-0.067*** 
(0.012) 
 
Vitality level 2      -0.016* 
(0.008) 
-0.028*** 
(0.010) 
-0.028*** 
(0.010) 
-0.033*** 
(0.011) 
-0.026*** 
(0.008) 
-0.016 
(0.012) 
 
Vitality level 3      -0.056*** 
(0.011) 
-0.044*** 
(0.011) 
-0.044*** 
(0.010) 
-0.049*** 
(0.011) 
-0.039*** 
(0.009) 
-0.056*** 
(0.012) 
 
Vitality level 4      -0.115*** 
(0.014) 
-0.115*** 
(0.013) 
-0.115*** 
(0.012) 
-0.122*** 
(0.013) 
-0.103*** 
(0.011) 
-0.115*** 
(0.015) 
 
Vitality level 5      -0.173*** 
(0.018) 
-0.173*** 
(0.011) 
-0.173*** 
(0.011) 
-0.179*** 
(0.011) 
-0.157*** 
(0.010) 
-0.173*** 
(0.014) 
 
Constant 0.966*** 
(0.010) 
0.983*** 
(0.015) 
1.015*** 
(0.016) 
 0.964*** 
(0.017) 
0.988*** 
(0.008) 
0.979*** 
(0.018) 
0.979*** 
(0.018) 
0.999*** 
(0.019) 
0.121*** 
(0.003) 
0.987*** 
(0.017) 
 
Observations 1,278 1,278 1,278  1,278 1,323 1,323 1,323 1,323    
Number of respondents 142 142 142  32 147 147 1347 147  33  
R2 0.165    0.870 0.236     0.955  
Number of inconsistencies 2 0 0  2 2 2 0 2  2  
Number of sig. variables 6 8 8  6 14 13 12 14  12  
RMSE 0.178 0.112 .  0.302 0.171 0.120 0.119   0.025  
MAE 0.117 0.118 0.116  0.116 0.118 0.119 0.119 0.118  0.118  
%states with AE>0.05 66.5 68.9 65.0  66.0 71.6 72.8 72.8 72.5  71.6  
%states with AE>0.10 43.8 43.7 42.0  43.4 46.1 45.9 45.8 45.2  46.1  
LB test 1.617 6.343 7.274  1.715 3.686 4.443 4.681 4.258  3.580  
*     Significant at 10%; **   Significant at 5%; *** Significant at 1% 
GLS, Generalised Least Square; LB, Ljung-Box; MAE, mean absolute error; OLS, ordinary least square; RE, random effects; RMSE, root mean squared error 
Figure 1: DHP-3D and DHP-5D health state classification systems  
 
DHP-3D 
Mood  
You never find yourself losing your temper over small things  
You sometimes find yourself losing your temper over small things   
You often find yourself losing your temper over small things   
You very often find yourself losing your temper over small things  
 
 
Social limitations  
Your days are never tied to meal times  
Your days are sometimes tied to meal times  
Your days are usually tied to meal times  
Your days are always tied to meal times  
 
 
Eating  
When you start eating you find it very easy to stop  
When you start eating you find it quite easy to stop  
When you start eating you find it not very easy to stop  
When you start eating you find it not at all easy to stop  
 
DHP-5D 
Mood  
You never find yourself losing your temper over small things  
You sometimes find yourself losing your temper over small things   
You often find yourself losing your temper over small things   
You very often find yourself losing your temper over small things  
 
 
Social limitations  
Your days are never tied to meal times  
Your days are sometimes tied to meal times  
Your days are usually tied to meal times  
Your days are always tied to meal times  
 
 
Eating  
When you start eating you find it very easy to stop  
When you start eating you find it quite easy to stop  
When you start eating you find it not very easy to stop  
When you start eating you find it not at all easy to stop  
 
 
Hypoglycemic attacks  
You never worry about doing too much and going hypo   
You sometimes worry about doing too much and going hypo  
You usually worry about doing too much and going hypo  
You always worry about doing too much and going hypo  
 
 
Vitality   
You are tired none of the time  
You are tired a little of the time  
You are tired some of the time  
You are tired most of the time  
You are tired all of the time  
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Figure 2: Histograms of observed DHP-3D (panel a) and DHP-5D (panel b) values 
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Figure 3: Observed vs predicted DHP-3D (panel a) and DHP-5D (panel b) values 
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